Evidence map›Paper›PMID 35480113›Full record

ArticleFrontiers in oncology2022

Rana S Moubarak, Lisa Koetz-Ploch, Gavriel Mullokandov, Avital Gaziel, Ana de Pablos-Aragoneses, Diana Argibay, Kevin Kleffman, Elena Sokolova, Marianne Berwick, Nancy E Thomas and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Rana S MoubarakDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Lisa Koetz-PlochDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Gavriel MullokandovDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Avital GazielDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Ana de Pablos-AragonesesDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Diana ArgibayDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Kevin KleffmanDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Elena SokolovaDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
Marianne BerwickDivision of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, United States.
Nancy E ThomasDepartment of Dermatology, University of North Carolina, Chapel Hill, NC, United States.
Iman OsmanInterdisciplinary Melanoma Cooperative Group (IMCG), New York University (NYU) Cancer Institute, New York, NY, United States.
Brian D BrownDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Eva HernandoDepartment of Pathology, New York University (NYU) School of Medicine, New York, NY, United States.
New York University · USEastern Cooperative Oncology Group · USIcahn School of Medicine at Mount Sinai · USUniversity of New Mexico · USUniversity of North Carolina at Chapel Hill · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1M
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSMAN, IMAN, WEBER, JEFFREY S · 2019 to 2025
$12.5M
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage MelanomaP01CA206980 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BERWICK, MARIANNE, THOMAS, NANCY E. · 2017 to 2022
$10.1M
NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA016087NCI NIH HHS P50 CA225450
6 · The paper itself

Abstract

Melanoma is a highly prevalent cancer with an increasing incidence worldwide and high metastatic potential. Brain metastasis is a major complication of the disease, as more than 50% of metastatic melanoma patients eventually develop intracranial disease. MicroRNAs (miRNAs) have been found to play an important role in the tumorigenicity of different cancers and have potential as markers of disease outcome. Identification of relevant miRNAs has generally stemmed from miRNA profiling studies of cells or tissues, but these approaches may have missed miRNAs with relevant functions that are expressed in subfractions of cancer cells. We performed an unbiased

Indexed as

brain metastasisMelanomametastasismicroRNAtumor suppressor

Identifiers

PMID35480113
PMCPMC9036958
OpenAlexW4223588907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.